YL-13027
N/A
Report date: 2022/07/19 20:00:45
NME
Base Information
Drug NameYL-13027
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesYL-Pharma
China Registration ClassClass 1 Chemical Drug in China
Develop Information
Active CompaniesShanghai HyaMab Biotech Co LtdYL-Pharma
Inactive Companies280 Bio IncThe University Of Texas MD Anderson Cancer Center
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A